QuickLinks -- Click here to rapidly navigate through this document
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):May 4, 2005
MYRIAD GENETICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware (State or other jurisdiction of incorporation) | 0-26642 (Commission File Number) | 87-0494517 (IRS Employer Identification No.) | ||
320 Wakara Way Salt Lake City, Utah 84108 (Address of principal executive offices) (Zip Code) | ||||
Registrant's telephone number, including area code:(801) 584-3600
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
- o
- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 2.02 Results of Operations and Financial Condition
On May 4, 2005, Myriad Genetics, Inc. announced its financial results for the three and nine months ended March 31, 2005. The earnings release is attached hereto as an exhibit to this Current Report on Form 8-K and is being filed pursuant to this Item 2.02 as Exhibit 99.1 to this Current Report on Form 8-K.
ITEM 9.01 Financial Statements and Exhibits.
- (c)
- The following exhibit is filed with this report:
| Exhibit Number | Description | |
|---|---|---|
| 99.1 | Earnings release dated May 4, 2005 for the three and nine months ended March 31, 2005. |
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
MYRIAD GENETICS, INC. | ||||
Date: May 4, 2005 | By: | /s/ PETER D. MELDRUM Peter D. Meldrum President and Chief Executive Officer | ||
3
| Exhibit Number | Description | |
|---|---|---|
| 99.1 | Earnings release dated May 4, 2005 for the three and nine months ended March 31, 2005. |
4
SIGNATURES
EXHIBIT INDEX